Going forward, global MD&D sales are projected to increase at a modest 4.6% real annual rate through 2017 to $446 billion. This slower growth reflects the dominance of the developed nations in the overall market, which are expected to see only about 2.4% real annual gains based on their already large sizes. Caseloads in the U.S., Europe and Japan are expected to rise significantly with population aging, the growing obesity and diabetes epidemics and, in the U.S., the gradual implementation of mandatory insurance. However, cost containment pressures will offset much of these gains, and priority will be given to new technologies-such as transcatheter heart valves, renal denervation technologies, and endoscopic devices-that can either replace costly therapies or enable early intervention and even prophylaxis for the more expensive medical conditions.
In contrast, emerging nations are expected to see annual growth in the 11% to 12% range as the individuals contributing to their economic growth demand better, more accessible health care. MD&D companies are contributing to this growth by specifically configuring products to the needs of those economies and the health care needs of their populations. This ability to adapt and innovate will remain a key factor in the future of the industry, as competition intensifies for increasingly scarce health care funds.
This comprehensive report published by Health Research International-and distributed exclusively by Life Science Intelligence-provides "must-have" expert analysis of the critical trends and developments impacting the MD&D market through 2017. It features more than 150 exhibits encompassing individual market, geographic, and competitive assessments for 19 major technology segments (100 individual product markets), including: cardiovascular technologies; in vitro diagnostics; orthopedics and spine; diagnostic imaging equipment and consumables; urology/renal; wound management; dental; ophthalmic surgery; critical care; energy-based therapies; and endoscopy, among others. These are complemented by statistics and discussions of the major clinical applications driving use of MD&D products, e.g., cardiovascular disease, musculoskeletal disease, cancer, diabetes, end-stage renal disease, and respiratory conditions.
The market models built from the demand side have been compared with and verified by supply-side data developed through detailed analyses of MD&D sales for 2004 through 2012 on more than 650 companies, of which the top 30 are profiled in detail in the report. The end result is what we believe is the most comprehensive and accurate assessment of developments in the global MD&D marketplace to date.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
